Lanvis

Tioguanine, the active ingredient in Lanvis, is a thiopurine presented as an oral tablet for oral use. It is employed in the treatment of certain hematologic malignancies, primarily in adult and pediatric patients requiring chemotherapy.\n\nGNH India supplies Lanvis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Tioguanine is a thiopurine antineoplastic agent used in the treatment of certain hematologic malignancies.\n\nAcute lymphoblastic leukemia: provides maintenance therapy to reduce relapse risk.\nAcute myeloid leukemia: incorporated into induction or consolidation regimens.\nChronic myeloid leukemia: used in specific disease phases as part of combination therapy.

Tioguanine may cause a range of adverse reactions.\n\nCommon Side Effects:\n- Nausea and vomiting\n- Myelosuppression (neutropenia, anemia, thrombocytopenia)\n- Elevated liver enzymes\n- Mucositis or oral ulceration\n- Rash or mild skin irritation\n\nSerious or Rare Side Effects:\n- Severe bone‑marrow failure leading to life‑threatening infections\n- Hepatic veno‑occlusive disease\n- Secondary malignancies\n- Pancreatitis\n- Severe hypersensitivity reactions including anaphylaxis\n- Neurological toxicity such as seizures

Before initiating therapy, several precautions should be observed.\n\nMonitor blood counts: perform regular complete blood count assessments.\nAssess liver function: schedule periodic liver enzyme tests.\nEvaluate renal function: adjust dosing if significant impairment is present.\nAvoid use in patients with known hypersensitivity to thiopurines.\nUse effective contraception during treatment and for a defined period after discontinuation.\nStore at ambient temperature: keep in the original pack, protect from moisture and light.

Tioguanine interacts with several medicines that may alter its safety or efficacy.\n\nMajor Interactions (Avoid):\n- Allopurinol: increases risk of severe myelosuppression.\n- Azathioprine: additive thiopurine toxicity.\n- Warfarin: may enhance anticoagulant effect.\n\nModerate Interactions (Monitor Closely):\n- NSAIDs: potential renal function impact.\n- Oral contraceptives: reduced hormonal efficacy.\n- Anticonvulsants (enzyme inducers): may lower tioguanine levels.